Study of Valsartan Treatment for Adults With Pulmonary Arterial Hypertension
A 24-Week Randomized, Placebo-Controlled Phase 2 Trial
Led by University of Washington · Updated on 2026-05-04
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Pulmonary arterial hypertension PAH causes strain on the right side of the heart, which can lead to right heart failure. Unlike left heart failure, there are currently no treatments directly targeting right heart function. Researchers are evaluating valsartan, a medication typically used for high blood pressure and left heart failure, to see if it can help strengthen the right heart in adults with PAH. This is a Phase 2 randomized placebo-controlled trial studying valsartans safety and clinical effect over 24 weeks.
Participants will be randomly assigned to take either valsartan 40 mg capsules or placebo capsules twice daily for 24 weeks. Study visits will occur at weeks 0, 2, 12, and 24, with most visits lasting 20 to 30 minutes in addition to usual clinic appointments. While visits at weeks 2 and 12 may be done remotely, echocardiograms will be done at the start and end of the study. Some participants may choose to undergo optional exercise testing or right heart catheterization at weeks 0 and 24.
During the study, participants will be monitored through clinical assessments including echocardiograms and questionnaires about heart function and quality of life. The main outcome measured is the six-minute walk distance over 24 weeks. Secondary outcomes include changes in heart function measurements, heart failure classification, biomarkers, quality of life scores, and frequency of increased pulmonary hypertension treatments. The total participation time is 24 weeks, with safety and clinical data collected throughout.
CONDITIONS
Brief Title
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Research Team
L
Laurie Hogl, RRT
N
Nancy Liston, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Valsartan 40 mg twice daily
Placebo
Current guideline-based PAH therapy
What it is
An investigational off‑label use of the ARB Valsartan given orally at 40 mg twice daily for 24 weeks
A matched oral placebo given twice daily for 24 weeks
Established use of targeted vasodilator therapies addressing endothelin, nitric oxide‑cGMP, prostacyclin or activin pathways per current guidelines
Role in trial
Investigational treatment being evaluated for efficacy and safety
Control arm used to compare against investigational drug
Represents guideline‑recommended current care not part of the trial
Primary intended use
To determine whether adding Valsartan improves functional capacity and cardiac status in PAH
Serve as placebo control to allow assessment of Valsartan effect
Guideline‑recommended therapy aimed at improving symptoms, exercise capacity, and outcomes in PAH
How it is given or performed
Oral administration: 40 mg twice daily for 24 weeks
Oral placebo given twice daily for 24 weeks matching investigational drug
Variable oral or inhaled agents targeting PAH pathways as per clinical guidelines
Evidence status
Efficacy in PAH not yet established — this trial is ongoing
No therapeutic effect; used to provide comparison
Proven to improve exercise capacity and outcomes in PAH per guidelines
Important limitations
This is a repurposing study; previous hemodynamic effects only supported in animal models and observational data
Placebo control does not reflect real‑world options
Guideline therapies vary by patient risk profile and require specialized follow‑up
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
Male or female, age 18 to 80
Diagnosed with WHO Group 1 Pulmonary Arterial Hypertension
NYHA Functional Class II, III, or IV at screening
Right heart catheterization within five years showing mean pulmonary arterial pressure 6 25 mmHg, occlusion pressure 6 15 mmHg, and resistance 6 3 wood units
If occlusion pressure is 15 - 20 mmHg, pulmonary vascular resistance 6 9 wood units and receiving PAH-specific therapy
Able to walk at least 50 meters with or without a walking aid
You will not qualify if you...
Pregnant or lactating
Pulmonary hypertension other than group 1 or veno-occlusive disease
History of interstitial lung disease unless specific lung function criteria met
Use of investigational drug or device within 30 days or during study
Use of ACE-inhibitor, ARB, or ARNI within 30 days before randomization
Left heart disease with ejection fraction less than 40%
Any other serious illness or abnormal labs that may risk participant or affect study data
Expected survival less than 1 year due to other diseases
Allergy or angioedema related to ACE-inhibitors
Potassium level above 5 mEq/L or serum creatinine above 2 mg/dL at screening
Systolic blood pressure below 90 mmHg at screening
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 24 weeks
Participants take valsartan or placebo twice daily to evaluate its effect on right heart function.
4 study visits at weeks 0, 2, 12, and 24; visits at weeks 2 and 12 may be completed remotely
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 129Xenon MRI and Spectroscopy to Monitor Response to Sotatercept Treatment in Adults with Pulmonary Arterial Hypertension
Using 129 Xenon MRI to Diagnose and Monitor Treatment in Pulmonary Arterial Hypertension
Including Idiopathic and Connective Tissue Disease-Associated Types
Pilot Study of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation Compared to Placebo in Adults With Pulmonary Arterial Hypertension
Observational Study of Healthy Pregnant Women at High Altitude and Sea Level in Bolivia
Tracking Heart and Baby Health During and After Pregnancy
Phase 1b2 Randomized Study Evaluating Safety and Effects of HS235 Added to Background Treatment in Adults With Pulmonary Arterial Hypertension
Evaluating Safety and Effects of Sotatercept in Japanese Children Aged 1 to 17 with Pulmonary Arterial Hypertension Receiving Standard Treatment
Safety Evaluation of Sotatercept With Standard Treatment for Adults With Pulmonary Arterial Hypertension in India
Study of Empagliflozin for Treating Adults with Pulmonary Arterial Hypertension to Assess Effectiveness and Safety
Evaluating the Safety and Effectiveness of Once Daily Treprostinil Palmitil Inhalation Powder Compared to Placebo in Adults with Pulmonary Arterial Hypertension
Phase 2 Open-Label Study of APL-9796 in Adults Aged 18 to 80 With Pulmonary Hypertension Using CardioMEMS PA Sensor
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database.